Cargando…

Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study

INTRODUCTION: Preoperative chemotherapy in patients undergoing resection for colorectal liver metastases (CLM) improves oncological outcomes. However, chemotherapy-associated liver injury (occurring in two patterns: vascular and fat deposition) is a real clinical concern prior to hepatic resection....

Descripción completa

Detalles Bibliográficos
Autores principales: Parmar, Kat L, O'Reilly, Derek, Valle, Juan W, Braun, Michael, Naish, Jo H, Williams, Steve R, Lloyd, William K, Malcomson, Lee, Cresswell, Katharine, Bamford, Colin, Renehan, Andrew G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513559/
https://www.ncbi.nlm.nih.gov/pubmed/32967864
http://dx.doi.org/10.1136/bmjopen-2018-027630
_version_ 1783586409129443328
author Parmar, Kat L
O'Reilly, Derek
Valle, Juan W
Braun, Michael
Naish, Jo H
Williams, Steve R
Lloyd, William K
Malcomson, Lee
Cresswell, Katharine
Bamford, Colin
Renehan, Andrew G
author_facet Parmar, Kat L
O'Reilly, Derek
Valle, Juan W
Braun, Michael
Naish, Jo H
Williams, Steve R
Lloyd, William K
Malcomson, Lee
Cresswell, Katharine
Bamford, Colin
Renehan, Andrew G
author_sort Parmar, Kat L
collection PubMed
description INTRODUCTION: Preoperative chemotherapy in patients undergoing resection for colorectal liver metastases (CLM) improves oncological outcomes. However, chemotherapy-associated liver injury (occurring in two patterns: vascular and fat deposition) is a real clinical concern prior to hepatic resection. After major liver resection, regeneration of the residual liver is a prerequisite for recovery and avoidance of liver failure, but this regenerative capacity may be hindered by chemotherapy. Thus, there is a need to predict for this serious complication. Over the past two decades, several tests and derived indices have been developed, which have failed to achieve clinical utility, mainly as they were indirect measurements of liver function. Here, we will use a novel test of liver function (the liver maximum capacity (LiMAx) test), and measure liver fat using MRI. METHODS AND ANALYSIS: This prospective study will assess changes in liver function longitudinally, measured by the LiMAx test, and liver fat, measured by advanced MRI using both MR spectroscopy and the modified Dixon method, in up to 35 patients undergoing preoperative chemotherapy for CLM. The primary outcomes will be the changes in liver function and fat compared with baseline prechemotherapy measurements. Secondary outcome measures include: routinely measured liver function blood tests, anthropometric measurements, postoperative histology and digital quantification of fat, postoperative complications and mortality and quality of life. ETHICS AND DISSEMINATION: The study was approved by a National Health Service Research Ethics Committee and registered with the Health Research Authority. Dissemination will be via international and national conferences and the National Institute for Health Research network. Manuscripts will be published. TRIAL REGISTRATION NUMBER: This study is registered online at www.clinicaltrials.gov (registration number NCT03562234).
format Online
Article
Text
id pubmed-7513559
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-75135592020-10-05 Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study Parmar, Kat L O'Reilly, Derek Valle, Juan W Braun, Michael Naish, Jo H Williams, Steve R Lloyd, William K Malcomson, Lee Cresswell, Katharine Bamford, Colin Renehan, Andrew G BMJ Open Oncology INTRODUCTION: Preoperative chemotherapy in patients undergoing resection for colorectal liver metastases (CLM) improves oncological outcomes. However, chemotherapy-associated liver injury (occurring in two patterns: vascular and fat deposition) is a real clinical concern prior to hepatic resection. After major liver resection, regeneration of the residual liver is a prerequisite for recovery and avoidance of liver failure, but this regenerative capacity may be hindered by chemotherapy. Thus, there is a need to predict for this serious complication. Over the past two decades, several tests and derived indices have been developed, which have failed to achieve clinical utility, mainly as they were indirect measurements of liver function. Here, we will use a novel test of liver function (the liver maximum capacity (LiMAx) test), and measure liver fat using MRI. METHODS AND ANALYSIS: This prospective study will assess changes in liver function longitudinally, measured by the LiMAx test, and liver fat, measured by advanced MRI using both MR spectroscopy and the modified Dixon method, in up to 35 patients undergoing preoperative chemotherapy for CLM. The primary outcomes will be the changes in liver function and fat compared with baseline prechemotherapy measurements. Secondary outcome measures include: routinely measured liver function blood tests, anthropometric measurements, postoperative histology and digital quantification of fat, postoperative complications and mortality and quality of life. ETHICS AND DISSEMINATION: The study was approved by a National Health Service Research Ethics Committee and registered with the Health Research Authority. Dissemination will be via international and national conferences and the National Institute for Health Research network. Manuscripts will be published. TRIAL REGISTRATION NUMBER: This study is registered online at www.clinicaltrials.gov (registration number NCT03562234). BMJ Publishing Group 2020-09-23 /pmc/articles/PMC7513559/ /pubmed/32967864 http://dx.doi.org/10.1136/bmjopen-2018-027630 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Oncology
Parmar, Kat L
O'Reilly, Derek
Valle, Juan W
Braun, Michael
Naish, Jo H
Williams, Steve R
Lloyd, William K
Malcomson, Lee
Cresswell, Katharine
Bamford, Colin
Renehan, Andrew G
Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study
title Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study
title_full Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study
title_fullStr Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study
title_full_unstemmed Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study
title_short Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study
title_sort prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the cliff study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513559/
https://www.ncbi.nlm.nih.gov/pubmed/32967864
http://dx.doi.org/10.1136/bmjopen-2018-027630
work_keys_str_mv AT parmarkatl prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT oreillyderek prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT vallejuanw prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT braunmichael prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT naishjoh prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT williamsstever prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT lloydwilliamk prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT malcomsonlee prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT cresswellkatharine prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT bamfordcolin prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy
AT renehanandrewg prospectivestudyofchangeinliverfunctionandfatinpatientswithcolorectallivermetastasesundergoingpreoperativechemotherapyprotocolforthecliffstudy